Patients with RM HNSCC treated with dasatinib showed no objective response, in spite of its ability to block Src kinase activity.56 Moreover, in a randomised trial of patients with operable HNSCC, dasatinib showed neither efficacy as a single agent nor any additive effect when combined with a tyrosine kinase inhibitor.57 Based on the data in the current study, it may be that tumour cells can switch to activate alternative pathways upon treatment with dasatinib and that it may be related, at least in part, to the action of Src on EPS8. This evidence concerns the gene SRC and neoplasm.